Eventide Asset Management - PROTEOSTASIS THERAPEUTICS IN ownership

PROTEOSTASIS THERAPEUTICS IN's ticker is PTI and the CUSIP is 74373B109. A total of 52 filers reported holding PROTEOSTASIS THERAPEUTICS IN in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Eventide Asset Management ownership history of PROTEOSTASIS THERAPEUTICS IN
ValueSharesWeighting
Q1 2017$845,000
-68.7%
108,000
-50.9%
0.06%
-68.0%
Q4 2016$2,697,000
-21.4%
220,0000.0%0.18%
-16.3%
Q3 2016$3,430,000
+41.4%
220,000
+10.0%
0.21%
+41.2%
Q2 2016$2,426,000
+25.8%
200,0000.0%0.15%
+37.0%
Q1 2016$1,928,000200,0000.11%
Other shareholders
PROTEOSTASIS THERAPEUTICS IN shareholders Q2 2017
NameSharesValueWeighting ↓
Cormorant Asset Management, LP 3,804,027$17,803,0002.95%
HARBOURVEST PARTNERS LLC 440,627$2,062,0000.89%
NEA Management Company, LLC 3,556,778$16,646,0000.61%
Rock Springs Capital Management LP 450,000$2,106,0000.11%
Bain Capital Public Equity Management, LLC 263,498$1,233,0000.07%
ELEMENT CAPITAL MANAGEMENT LLC 65,973$309,0000.06%
Hillhouse Capital Management 865,923$4,053,0000.06%
SABBY MANAGEMENT, LLC 125,151$586,0000.04%
Marshall Wace North America L.P. 684,124$3,421,0000.02%
FNY Partners Fund LP 20,127$94,0000.02%
View complete list of PROTEOSTASIS THERAPEUTICS IN shareholders